Novavax (NVAX) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -45.60%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.04 per share when it actually produced a loss of $1.05, delivering a surprise of -0.96%. Over the last four quarters, the company has ...

Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnership Phase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025 Company to host conference cal ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Select Market Non-accelerated filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION ...

In the latest market close, Novavax (NVAX) reached $12.57, with a -1.87% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 1.37%. On the other hand, the Dow registered a loss of 1.21%, and the technology-centric Nasdaq decreased by 2.3%. The vaccine maker's shares have seen an increase of 2.07% over the last month, surpassing the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11%. Investors will be eagerly watching for the performance of Novava ...

GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3XTduSS Dial-in number: (800) 836 ...

Earlier, Novavax received a substantial financial boost due to its strategic partnership with French pharmaceutical and healthcare firm Sanofi (NASDAQ:SNY). The partnership – inked on May 10 – centers on a Covid vaccine program called Nuvaxovid and involved a $500 million upfront milestone payment, alleviating "concerns about the company's financial stability." However, the belief among JPMorgan analysts now is that, prior to today's implosion, NVAX stock prices "substantially overvalue" the sales that Nuva ...

Investment Overview Novavax Seals Sensational Sanofi Deal In Q1 2024 Prior to Q1 earnings Novavax had warned investors that "conditions or events existed that raised substantial doubt about our ability to continue as a going concern" - the reasons for this can be traced to its failure to establish its COVID vaccine, Nuvaxovid, alongside Moderna's (MRNA) Spikevax and Pfizer's (PFE) Comirnaty as a preferred vaccine option for major governments' - here is what I wrote in May: Novavax is arguably best known for ...

Zacks Investment Research Image Source: This surge in share price can be attributed to Novavax's recently signed multi-billion dollar deal with pharma giant Sanofi (SNY) to market its protein-based COVID-19 vaccine and also use it to develop novel COVID-19- influenza combination vaccines. The positive cashflows generated from this deal were a major reason that the company removed its 'going concern' warning. Solid Partner in Sanofi The collaboration deal with Sanofi likely breathes new life for Novavax, whi ...

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Earnings Estimate Revisions Our analysis is ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firm ...